Abstract
Lipoprotein(a), (Lp(a)) level was measured in Japanese hospitalized controls and various liver disease groups, and lowest in liver cirrhosis (LC) and highest in acute hepatitis (AH). Lp(a) level was higher in AH rather than in controls. Difference of Lp(a) levels was statistically significant between AH and LC, and fatty liver (FL) and AH. It is suggested that catabolism of Lp(a) is more altered in AH than in LC, and Lp(a) reacts as an acute phase protein much more in AH than in LC. Statistically significant increase of Lp(a) levels was recognized in responders to Interferon therapy for chronic hepatitis-C, whereas not significant in non-responders. This indicates that increased Lp(a) levels represent an improved liver function. The results clearly suggest that liver diseases modulate the Lp(a) metabolism.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
